A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Fox Chase Cancer Center, part of the Temple University Health System, is committed to clinical excellence, research expertise, and community health. These initiatives earned us a National Cancer Institute (NCI) designation as one of the first comprehensive cancer centers in the country and one of only 50 in the nation to earn this full designation by the federal government’s principal agency for cancer research and training.
Philadelphia, Pennsylvania Clinical Trial Location
Fox Chase Cancer Center
333 Cottman Ave,
Philadelphia, PA 19111